Navigation Links
More Evidence That Early Treatment Can Stop HIV's Spread to Partners
Date:7/18/2011

By Steven Reinberg
HealthDay Reporter

MONDAY, July 18 (HealthDay News) -- Researchers on Monday released yet more evidence that early treatment of HIV in an infected heterosexual can protect his or her partner from becoming infected.

The study, conducted among 1,763 couples in Africa, Asia, South America and the United States, found that HIV-infected people in stable sexual relationships cut their odds of transmitting the virus to their partner by 96 percent if they got antiretroviral medications soon after diagnosis.

The findings were published online ahead of print in the New England Journal of Medicine to coincide with their presentation on Monday at the International AIDS Society Conference in Rome.

To the question of whether early treatment helps shield sexual partners from infection, the answer from this study "was a resounding yes," Dr. Scott Hammer, professor of medicine at Columbia University, New York City, wrote in an accompanying journal editorial.

The new findings come on the heels of similar research released July 13 by the U.S. Centers for Disease Control and Prevention. In two separate studies, scientists found that giving antiretroviral drugs to heterosexuals at high risk of HIV infection significantly reduced their chances of developing the AIDS-causing virus.

Speaking to HealthDay at the time, Dr. Jared Baeten, co-chair of one study and a University of Washington associate professor of global health, called that outcome "an extremely exciting finding for the field of HIV prevention."

In the latest study in NEJM, a team led by Dr. Myron S. Cohen at the University of North Carolina at Chapel Hill tracked outcomes for couples where one partner was HIV-positive and the other was not (evenly split between males and females carrying the virus). The infected partner was randomized to receive a combination of a variety of standard HIV-suppressing medications, either immediately after their diagnosis or in a delayed fashion (for example, until their immune cell counts reached a certain low level, or when HIV-linked symptoms appeared).

Enrollment in the trial began in June of 2007 and by the end of February 2011 the team used gene-based methods to confirm 28 cases where a previously uninfected partner had contracted the virus from his or her HIV-positive mate.

In only one of the 28 cases, the transmission had occurred in a couple randomized to the early-treatment group.

"The sustained suppression of HIV-1 in genital secretions resulting from antiretroviral therapy is the most likely mechanism for the prevention of HIV-1 transmission that we observed," Cohen's team wrote.

They also found early treatment to be associated with a 41 percent drop in HIV-linked "clinical events" -- sickness and/or death -- in HIV-infected patients, compared with those whose treatment was delayed.

The findings echo those reported by the CDC last week. Both of the CDC trials were done in Africa. In one, a daily dose of Truvada, a combination pill that includes tenofovir disoproxil fumarate and emtricitabine, reduced the risk of contracting HIV from infected partners by about 63 percent.

The other study found that two different regimens -- tenofovir, sold as Viread, and Truvada -- also reduced the risk of transmission through heterosexual sex.

No significant safety concerns were associated with Truvada, the study said, although people taking it were more likely to report nausea, vomiting and dizziness than those taking placebo.

Using antiretrovirals in this way is called pre-exposure prophylaxis, or PrEP.

Earlier research has found that PrEP reduced HIV transmission among gay and bisexual men, but whether it could prevent HIV infection among heterosexuals had remained unknown.

"Now, more than ever, the priority for HIV prevention research must be on how to deliver successful prevention strategies, like PrEP, to populations in greatest need," Baeten said last Wednesday.

Based on the recent findings, the CDC will start working to develop guidance on the use of PrEP among heterosexuals in the United States, the agency said.

"To use PrEP in the United States we would use basically the same guidelines -- someone who is truly at risk for HIV," said Dr. Margaret A. Fischl, professor of medicine and director of the AIDS Clinical Research Unit and co-director of the University of Miami Developmental Center for AIDS Research, commenting on the studies released July 13.

Those at high-risk have multiple sex partners, use intravenous drugs or have multiple sexually transmitted diseases, Fischl said. "You are talking about a group that is at risk for multiple sexually transmitted diseases including HIV," she said.

However, it might be difficult to get the drugs to the people who need them, Fischl added.

"In addition, we need to identify people with HIV and get them into care, because in doing that we know that we decrease the transmission of HIV," Fischl said.

More information

For more information on HIV/AIDS, visit AIDS.gov.

SOURCES: July 18, 2011, New England Journal of Medicine, online; Margaret A. Fischl, M.D., professor, medicine, director, AIDS Clinical Research Unit, co-director, University of Miami Developmental Center for AIDS Research; July 13, 2011, teleconference with Jared Baeten, M.D., Ph.D., associate professor, global health, University of Washington


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
2. Evidence-based care and outcomes improve at Get With The Guidelines-Stroke hospitals
3. Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis
4. More Evidence That Swings in Blood Pressure Raise Stroke Risk
5. Cellular pathway could provide evidence of how cancer and obesity are linked
6. Palladians Distinguished Clinicians Present at APTAs National CSM Convention in San Diego on Evidenced Informed Management of Chronic Low Back Pain Without Surgery
7. Pew Applauds Federal Grant Program Supporting State Expansion of Evidence-Based Home Visitation
8. Elseviers Journal of Evidence-Based Dental Practice celebrates 10th year with special issue
9. Evidence-based medicine theory can be applied to frequent flying says US professor
10. No Evidence That Lithium Helps in ALS
11. UNC study offers first clinical evidence of anti-cancer drug triggering viral infection
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More Evidence That Early Treatment Can Stop HIV's Spread to Partners
(Date:4/30/2016)... , ... April 30, 2016 , ... Orlando-based Maximized Living ... they go for gold in Rio. Under the care of Maximized Living doctors ... , In an unprecedented showing, Maximized Living is sending the largest contingent of elite ...
(Date:4/29/2016)... ... April 29, 2016 , ... Since launching its annual volunteer ... serving the footwear industry, has broken all previous participation records in its first ... 23 states during the months of April and May, the 2016 Footwear Cares ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... On Tuesday, ... hospitals across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, ... Geoff Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s (GLA) ... with sunny skies, a light breeze and temperatures in the 60s. Over 400 runners, ... Run and Walk and 1-mile walk were held to increase awareness about Lyme ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... that student team BioCellection won the $30,000 Perlman Grand Prize of the 2016 ... Gloeckner Undergraduate Award, the Michelson People’s Choice Award, and the Committee Award for ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... 27, 2016  Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended March 26, ... $0.24 increased 41.2%, and non-GAAP diluted EPS of ... 5.8% on a reported basis, and 6.3% on ... posted another good quarter, highlighted by 14.6% growth ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
Breaking Medicine Technology: